CDC NEWS


powered by Surfing Waves


Latest News


AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis


23 Mar 2021

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favorable reactogenicity and overall safety profile


Experts Discuss COVID-19—Vaccine Questions, School Openings, and More


17 Mar 2021

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the COVID-19 pandemic. Comments have been edited for clarity.


CDC Interim Recommendations for Fully Vaccinated People


10 Mar 2021

On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million people, or 9.4% of the total population, have completed a vaccination series.


Approaches for Optimal Use of Different COVID-19 Vaccines Issues of Viral Variants and Vaccine Efficacy


04 Mar 2021

The efforts of the Biden administration to accelerate rollout of COVID-19 vaccines are enabling more adults in the US to be vaccinated each week. As of February 28, 2021, an estimated more than 48 million people have received at least 1 vaccine dose.


How the Johnson & Johnson Vaccine Works


28 Feb 2021

Johnson & Johnson is testing a coronavirus vaccine known as JNJ-78436735 or Ad26.COV2.S. Clinical trials showed that a single dose of the vaccine had an efficacy rate of up to 72 percent. The vaccine has been authorized for emergency use in the United States and Bahrain.




Articles


How the Novavax Vaccine Works


03 Feb 2021

The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials.




Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic


19 Jan 2021

Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the cause of coronavirus disease 2019 (COVID- 19), is a transmissible virus that infects the upper and lower respiratory tract, leading to a high viral titer in saliva and respiratory secretions.




COVID-19 as the Leading Cause of Death in the United States


12 Jan 2021

The current exponential increase in coronavirus dis- ease 2019 (COVID-19) is reaching a calamitous scale in the United States, potentially overwhelming the health care system and causing substantial loss of life.




Feds Authorize $22 Billion to Boost Vaccine Rollout


11 Jan 2021

The CDC will send $3 billion to the states to boost a lagging national COVID-19 vaccination program.




COVID-19 Immunity Could Last Longer Than 8 Months, Study Says


08 Jan 2021

Certain antibodies and memory cells likely last more than 8 months after someone has contracted the coronavirus, especially if they have a strong immune response to COVID-19, according to a new study published Wednesday in Science.




Enroll for Free